Top Markets
Coin of the day
NervGen Pharma Corp. NervGen Pharma Corp.

NervGen Pharma Corp.

NGEN
Rangering i aksjer #16729
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical... NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Aksjekurs
$3.78
Sist synkronisert: 2026-03-17
Markedsverdi
$276.54M
Endring (1 dag)
0.00%
Endring (1 år)
45.53%
Land
CA
Handel NervGen Pharma Corp. (NGEN)

Kategori

EPS for NervGen Pharma Corp. (NGEN)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til NervGen Pharma Corp. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for NervGen Pharma Corp. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH